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Abstract
Purpose To evaluate morphological and functional chorior-
etinal changes 5 years after standard photodynamic therapy
(PDT) for chronic central serous chorioretinopathy (CSC).
Methods A retrospective, nonrandomized study, including
patients with chronic CSC treated with standard PDT and
followed for at least 60 months. All patients underwent a
complete ophthalmological examination, and the location
and number of treatments were registered. Five or more
years after treatment, subfoveal and non-subfoveal treated
areas were evaluated with Spectralis optical coherence to-
mography and microperimetry.
Results Seventeen eyes of 15 patients were included, with
mean age of 48.3±8.4 years and a mean follow-up of 80.6±
12.4 months (range from 62 to 104 months). All eyes had
neurosensory detachment (NSD) at baseline. Treatment was
performed under the fovea in 58.8 % and in a non-foveal
area in 41.2 % of the eyes. At the final visit all eyes had
resolution of the NSD, with a statistical significant reduction
in central macular thickness (p=0.005) and preserved neuro-
retinal thickness (p=0.839). There was a statistical differ-
ence between initial and final BCVA (p<0.001) and a mean
gain of 8.4±7.8 letters. Subfoveal morphological changes in
external limiting membrane (ELM) and in photoreceptor inner
and outer segment junction (IS/OS) were correlated with final
BCVA (p=0.015 and p=0.014 respectively), but not with the
variation of BCVA. There was a statistical correlation between
morphological changes in IS/OS line and retinal sensitivity in
the central 12° and 2° (p=0.003 and p=0.002 respectively).
The morphological changes in the subfoveal layers were not
dependent on treatment location (p=0.154, p=0.644, and
p=1.0 for ELM, IS/OS line, and retinal pigment epithelium
respectively). Subfoveal final mean choroidal thickness was
295.1±68.7 μm, and showed no statistical difference from the
normal population (p=0.633).
Conclusions Morphological and functional chorioretinal
changes, observed 5 or more years after standard PDT for
chronic CSC, were not correlated with the location of treat-
ment, neither with the progression of visual acuity or with the
location of treatment, and are more likely to be related to the
disease itself than with the treatment provided.
Keywords Central serous chorioretinopathy .Photodynamic
therapy . Retinal layers morphology . Retinal sensitivity .
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Introduction
The pathogenesis of central serous chorioretinopathy (CSC) is
poorly understood, but choroidal hyperpermeability leading to
increased permeability of the retinal pigment epithelium
(RPE) and accumulation of subretinal fluid (SRF) has been
implicated [1, 2]. The high rate of spontaneous resolution
provides that conservative management can be adopted as
first-line treatment in most cases [3]. Photodynamic therapy
(PDT) with verteporfin has shown good results, both anatomic
and functional, in treating chronic CSC, with either standard
or reduced fluence (600 mW/cm2, 300 mW/cm2 respectively)
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and with either standard or half dose (6 mg/m2 or 3 mg/m2
respectively) [4–16]. However, it has been reported that PDT
can be associated with potential side-effects, such as RPE
atrophy, neuroretinal thickness (NRT) thinning, development
of choroidal neovascularization (CNV), and reduction in mac-
ular function [15–19]. All of these complications were
reported in short follow-up studies, and PDT long-term effects
in retinal morphology and function are still unknown.
The purpose of this study is to characterize functional and
morphological chorioretinal changes 5 years after standard
PDT for chronic CSC.
Material and methods
A retrospective, observational, nonrandomized study was
performed in 17 eyes of 15 patients with chronic CSC, 5
or more years after standard PDT. At the final visit, all eyes
underwent Spectralis optical coherence tomography (OCT)
and microperimetry for morphological and functional cho-
rioretinal evaluation.
Chronic CSC was defined as diffuse or poorly defined
widespread areas of leakage in fluorescein angiography
(FA), from broad areas of RPE damage. Inclusion criteria
were: (1) chronic CSC diagnosed by FA and confirmed by
indocyanine green angiography (ICGA) and OCT, (2) persis-
tent CSC longer than 6 months of duration or RPE changes
induced by multifocal recurrent detachment associated with
symptoms of chronic CSC lasting at least 6 months, (3) more
than 5 years of follow-up, (4) patient with 18 years or older, (5
absence of spontaneous resolution or improvement induced
by empirical treatment such as acetazolamide or ketoconazole,
or (6) presence of written informed consent for all patients.
Eyes were excluded if additional diagnoses that could com-
promise visual acuity were present, if previous treatment with
laser photocoagulation was performed, or if hypersensitivity
to fluorescein or any other condition that might contraindicate
PDT or angiographic exams were present.
At the baseline, clinical assessment included best-corrected
visual acuity (BCVA) with Early Treatment of Diabetic Ret-
inopathy (ETDRS) chart, slit-lamp biomicroscopy with a con-
tact lens or a noncontact lens, indirect ophthalmoscopy, FA
(TRC-50IA, Topcon, Tokyo, Japan), ICGA (TRC-50IA, Top-
con, Tokyo, Japan), and OCT (OCT Stratus 3-Carl Zeiss
Meditec, Dublin, CA, USA). The Stratus OCTwas performed
to measure initial and final NRT (markers were placed be-
tween the internal limiting membrane and the anterior limit of
the SRF, on the smaller thickness of the retina) and central
macular thickness (markers were placed between the internal
limiting membrane and the RPE, without including it).
All patients were treated with verteporfin (Visudyne,
Novartis AG, Basel, Switzerland) ICGA-guided PDT using
standard treatment parameters, according to the standard
protocol for CNV secondary to age-related macular degen-
eration (treatment of age-related macular degeneration
(TAP) Study Group 1999) [20]. The verteporfin was infused
(6 mg/m2) for 10 min followed by delivery of an activating
light dose of 50 J/cm2 from a 689 nm laser system (Carl
Zeiss, Dublin, CA, USA) with an exposure time of 83 s. The
laser spot size for the PDTwas the diameter of the choroidal
hyperpermeability area, indentified in the ICGA, plus 1 mm.
The number of treatments and the size of the spot were
registered. The treatment location was also registered as
foveal (less than 500 μm from the center of the foveal
avascular zone) or non-foveal (more than 500 μm from the
center of the foveal avascular zone).
Evaluations were performed each 3 months in the first year,
each 6 months in the secondyear and annually after the
secondyear. BCVA and OCT were performed in all visits.
FA and ICGAwere performed when necessary. Patients were
re-treated based on clinical evidence of reappearance or per-
sistence of neurosensory detachment (NSD), showed on OCT.
Improvement in BCVAwas considered when a gain of 5
or more letters was achieved, and visual loss when there was
a decrease of at least 5 letters in relation to initial BCVA.
At the final visit, Spectralis OCT (Spectralis Heidelberg
Engineering Inc., Heidelberg, Germany) was used to evaluate
retinal morphology of the subfoveal and treated areas (when
non-coincident), to determine the presence of SRF and to
measure treated retinal thickness, using the attached measur-
ing software in the Spectralis OCT. Treated retinal thickness
was defined as the smallest thickness in the central 500 μm in
diameter of the treated retina. The study of the morphology of
the outer retinal layers was performed at the level of the central
macula and treated retina, and included assessment of the
external limiting membrane (ELM), photoreceptor inner and
outer segment junction (IS/OS), and RPE. ELMwas classified
as normal or absent; IS/OS line was classified as normal, with
interruptions, or absent; RPE was classified as normal or with
atrophy. The layers were defined as normal when they were
detected as a continuous line, without any defect. The layers
were classified with interruptions when they presented with
point defects less than 200 μm within the studied area, and
were classified as absent if there was a discontinuity of more
than 200 μm in the studied layer. An atrophic layer was
referred to a diffuse loss of tissue in a present line.
At the final visit macular microperimetry was also per-
formed, using microperimeter-1 (MP-1) software (Niked,
Vigonza, Italy). The MP-1 provides a 45° view of the retina
with automated correction for eye movements. Goldmann
III stimuli with a white background and a 4–2 threshold
strategy were used. A circular test grid with 45 stimulus
points covering an area of 12° in diameter was applied. The
mean retinal sensitivity (RS) within the central 2° and 12° in
diameter was calculated. The microperimetry sensitivity was
also measured in the central 500 μm of the treated retina.
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At the final visit, choroidal thickness (CT) was measured
with enhanced depth imaging spectral-domain optical coher-
ence tomography (EDI OCT) by positioning the Spectralis
OCT close enough to the eye to obtain an inverted image.
Horizontal sections of 9 mm, which contain 100 average
scans, were obtained and the CT was manually measured
using the contained Heidelberg software. CT was defined as
the vertical distance from the hyperreflective line of Bruch’s
membrane to the innermost hyperreflective line of the chorio-
scleral interface. The central subfoveal CT of both eyes and
the CT below the smallest thickness of treated retina of the
affected eye were registered. Data from a pilot study reporting
the CT of normal eyes, that were measured using the same
techniques, in a population with similar age to our study, were
used to compare with our results [21].
For statistical analysis, SPSS software version 20.0 (SPSS
Inc, Chicago, IL, USA) was used. The level of statistical
significance was calculated with Kruskal–Wallis test, Mann–
Whitney U-test, Fisher’s exact test, paired samples test, inde-
pendent sample test and one-sample test depending on the
type and distributions of the samples. The statistic correlations
were calculated using the Pearson correlation or the Spear-
man’s rho correlation. A P value less than 0.05 or 0.01,
according to the sample and test performed, was considered
statistically significant. Written informed consent was
obtained from all subjects, and the study was conducted in
accordance with the tenets of the Declaration of Helsinki and
after institutional review board approval.
Results
Table 1 summarizes the clinical characteristics of the patients
and treatment results. Seventeen eyes of 15 patients with
chronic CSC treated with standard dose PDTwith verteporfin
were included, with a mean follow-up of 80.6±12.4 months
(range from 62 to 104 months).
ICGA-guided PDT was applied at the foveal area in ten
eyes (58.8 %) and in non-foveal area in seven eyes (41.2 %),
with a mean spot size of 3326.5±1061.9 μm (range from
1,200 to 5,400 μm).
The initial mean BCVA was 62.5±19.6 letters (Snellen
equivalent 20/63+3), which ranged from 10 to 85 letters, and
the final mean BCVA was 70.9±20.4 letters (Snellen equiva-
lent 20/40+1), which ranged from 20 to 90 letters. A statistically
significant improvement in BCVA (p<0.001, paired samples
test) was registered, with a mean gain of 8.4±7.8 letters (range
from loss of two letters to gain of 25 letters). Figure 1 shows
the evolution of BCVA during the follow-up. There was also a
statistically positive correlation between initial and final BCVA
(R Pearson=0.925 and Spearman’s rho=0.752, p<0.001). At
the final visit, 12 eyes (70.6 %) improved vision (gain of 5 or
more letters) and five eyes (29.4 %) remained unchanged.
There was no statistical difference in final BCVA between eyes
that were treated in the foveal or in the non-foveal area
(p=0.583, independent samples test).
During the follow-up, the mean number of treatments
was 1.1±0.3. Of the two eyes that underwent two sessions
of treatment, one was re-treated after 2 years and the other
was re-treated after 7 years of the first treatment. In these
two eyes, the re-treatment was performed in the same area
and for the same leakage spots as the primary PDT.
At the baseline, all eyes had NSD and no eyes had intra-
retinal fluid. The mean CMT was 257.9±128.4 μm (74–
597 μm) and the mean central NRT was 160.1±57.4 μm
(49–290 μm). There was a statistical difference between
initial and final CMT (p=0.005, paired samples test) which
decreased to 176.2±60 μm (40–318 μm). However, NRT
remained stable during the 5 or more years after PDT, which
ranged from 160.1±57.4 μm to 159.2±56.4 μm (p=0.839,
paired samples test). Final CMT and NRT were statistically
correlated with final BCVA (R Pearson=0.80, p<0.001; R
Pearson=0.76, p<0.001; respectively).
At the final visit, we studied the morphology of the outer
retinal layers, at subfoveal area and at the treated retina, with
Spectralis OCT, and correlated themwith final BCVA. Table 2
summarizes the morphological changes found 5 years after
PDT, and Table 3 shows the correlation with final BCVA. In
the subfoveal area, ELM was normal in 15 eyes (88.2 %) and
absent in two eyes (11.8 %). In these two eyes, baseline
Stratus OCT already showed retinal atrophy (NRT of 49 and
82 μm). Morphological changes found in subfoveal ELM
were correlated with final BCVA (p=0.015, Mann–Whitney
U test), but showed no correlation with the variation of BCVA
(p=1.0, Mann–Whitney U test). Subfoveal IS/OS line was
classified as normal in six eyes (35.3 %), with interruptions in
eight eyes (47.1%) and as absent in three eyes (17.6%). There
was also a statistical correlation between IS/OS line morphol-
ogy and final BCVA (p=0.014, Kruskal–Wallis test), but the
difference in BCVAwas only statistically significant between
the normal and absent groups (p=0.011, Kruskal–Wallis test).
As it was with the ELM, the alterations found in IS/OS line did
not correlate with the variation of BCVA (p=0.507, Kruskal–
Wallis test). In relation to RPE, the morphology of the layers
was classified as normal in five eyes (29.4 %) and with
atrophy in 12 eyes (70.6 %). There was no statistical correla-
tion between the RPE morphology and final or variation of
BCVA (p=0.064 and p=0.646 respectively; Mann–Whitney
U test). Only two eyes in this study had a final BCVA less than
30 letters, and both eyes improved vision after treatment (case
3 and 4). Spectralis OCT in these eyes showed an absent ELM
and IS/OS line and RPE atrophy. Baseline Stratus OCT al-
ready showed retinal atrophy.
Final morphological changes described above were present
in the fovea, independent on treatment location, whether it was
performed in the foveal or in the non-foveal area (p=0.154,
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p=0.644 and p=1.0, for ELM, IS/OS line, and RPE respec-
tively; Fisher’s exact test).
Spectralis OCT was also used to evaluate morphological
changes and retinal thickness in the treated area. The mean
treated retinal thickness was 222.8±78.5 μm (range from
141 to 406 μm). In the smallest thickness of the treated
retina, ELM was normal in 12 eyes (70.6 %) and absent in
five eyes 29.4 %); IS/OS line was normal in four eyes
(23.5 %), interrupted in six eyes (35.3 %), and absent in
seven eyes (41.2 %); RPE was normal in four eyes (23.5 %)
and atrophic in 13 eyes (76.5 %).
Table 2 shows the final RS in the central 12° and 2° and in
the treated retina, and Table 3 shows correlation with morpho-
logical changes. The final mean RS within the central 12° and
2° were 15.9±5.1 dB (range 1.8–19.9 dB) and 14.8±5.2 dB
(range 2.2–19.7 dB) respectively, and were statistically corre-
lated with final BCVA (R Pearson=0.86 and p<0.001,
R Pearson=0.90 and p<0.001 respectively), but not with the
variation of BCVA. The mean microperimetry within the
treated retina was 11.7±6.5 dB (range 0–19.6 dB) and showed
no correlation with laser spot PDT size. Central 2° RS was
correlated with CMT (Pearson=0.87, p<0.001; Spearman’s
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Table 1 Clinical changes in BCVA, central macular thickness, neuroretinal thickness and choroidal thickness
Patient
no.
Gender Eye Age Follow-up
(months)
PDT Baseline Final follow-up
No. Local BCVA
(letters)
CMT
(μm)
NRT
(μm)
BCVA
(letters)
CMT
(μm)
NRT
(μm)
SF CT
(μm)
PDT CT
(μm)
1 M OD 42 76 1 Foveal 52 174 157 50 158 143 356 356
2 M OS 53 73 1 Foveal 50 224 182 65 201 182 253 253
3 M OD 47 104 1 N-foveal 25 74 49 30 40 40 300 100
4 M OS 47 104 1 N-foveal 10 232 82 20 71 62 325 248
5 M OD 48 84 1 N-foveal 70 398 224 90 232 224 330 304
6 M OD 60 69 1 Foveal 65 157 107 65 164 157 232 232
7 M OS 61 70 1 Foveal 78 315 199 85 209 199 201 201
8 M OD 42 62 1 Foveal 80 149 149 90 190 149 284 284
9 M OD 45 74 1 Foveal 70 182 182 79 173 162 246 246
10 M OD 65 66 2 N-foveal 83 456 290 85 318 290 173 124
11 M OD 45 77 1 Foveal 65 257 116 63 141 116 333 333
12 F OD 51 77 1 Foveal 70 190 124 75 175 155 255 255
13 M OD 53 88 1 Foveal 60 291 141 85 183 141 217 217
14 M OD 46 92 1 N-foveal 70 597 174 79 197 174 397 403
15 M OS 46 92 2 N-foveal 65 157 157 80 165 157 372 310
16 M OD 32 74 1 N-foveal 85 273 165 85 179 165 356 330
17 M OS 38 88 1 Foveal 65 259 224 80 199 190 387 387
Mean – – 48.3 80.6 1.1 – 62.5 257.9 160.1 70.9 176.2 159.2 295.1 269.6
SD – – 8.4 12.4 0.3 – 19.6 128.4 57.4 20.4 60 56.4 68.7 83
M male; F female; SD standard deviation; N-foveal non-foveal area; BCVA best-corrected visual acuity. CMT central macular thickness; NRT
neuroretinal thickness; SF CT subfoveal central choroidal thickness; PDT CF choroidal thickness in the smallest treated retina
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rho=0.90, p<0.001). In the central 12° and 2°, RS was statis-
tically correlated with subfoveal morphological changes in
ELM (p=0.015, Mann–Whitney U test) and IS/OS line
(p=0.003 and p=0.002 respectively, Kruskal–Wallis test).
Considering IS/OS line changes, RS within the central 12°
and 2° was better in the normal than in the absent group
(p=0.003 and p=0.002 respectively, Kruskal-Wallis test). In
the treated retina, IS/OS line morphological changes were
statistically correlated with RS (p=0.027, Kruskal–Wallis test)
and a statistical difference between the normal and absent
group was also registered (p=0.022, Kruskal–Wallis test).
There was no statistical correlation between the morphological
changes in RPE and RS, in the subfoveal or in the treated
retina. There was also no statistical correlation between the
morphological changes in ELM and RS in the treated retina.
Representative cases correlating retinal function and mor-
phology are shown (Figs. 2 and 3).
The final subfoveal CT of the treated eyes and was 295.1±
68.7μm (range 173–397μm), andwhen compared to a normal
population, with a mean age of 52 years, in which the sub-
foveal CT is about 287 μm, there was no statistical difference
(p=0.633, one-sample test). Excluding the eyes with active
bilateral disease (four eyes), the subfoveal CT of the treated
eyes was 278.7±67.6 μm and showed no difference from the
Table 2 Retinal morphological changes in subfoveal and treated retina area; retinal sensitivity in central 12° and 2° and in treated retina, at final
follow-up
Patient no. Subfoveal área Treated retina area MP-1 (dB)
ELM IS/OS line RPE ELM IS/OS line RPE Central 12º Central 2º Treated retina
1 Normal Interruptions Atrophy Normal Interruptions Atrophy 17.13 11.15 3.20
2 Normal Normal Atrophy Normal Normal Atrophy 19.64 18.77 17.20
3 Absent Absent Atrophy Absent Absent Atrophy 1.82 2.15 0
4 Absent Absent Atrophy Absent Absent Atrophy 5.11 5.23 0
5 Normal Normal Normal Absent Absent Normal 19.38 19.69 16.80
6 Normal Interruptions Normal Normal Interruptions Normal 12.18 12.92 14.00
7 Normal Normal Normal Normal Normal Normal 18.93 18.00 16.40
8 Normal Interruptions Atrophy Normal Interruptions Atrophy 16.89 18.46 17.00
9 Normal Interruptions Atrophy Normal Interruptions Atrophy 18.76 17.23 15.60
10 Normal Normal Normal Normal Normal Atrophy 19.87 19.54 19.60
11 Normal Absent Atrophy Normal Absent Atrophy 15.24 10.00 6.80
12 Normal Interruptions Atrophy Normal Interruptions Atrophy 15.98 13.31 10.60
13 Normal Normal Normal Normal Normal Normal 19.47 18.77 16.40
14 Normal Interruptions Atrophy Absent Absent Atrophy 18.36 16.77 14.60
15 Normal Interruptions Atrophy Normal Absent Atrophy 16.04 12.95 4.40
16 Normal Normal Atrophy Absent Absent Atrophy 18.09 18.54 11.00
17 Normal Interruptions Atrophy Normal Interruptions Atrophy 18.18 18.54 16.00
MP-1 retinal sensitivity measured by microperimeter-1; Central 12° central 12° retinal sensitivity; Central 2° central 2° retinal sensitivity
Table 3 Final mean BCVA and central 12 and 2° retinal sensitivity
according to the subfoveal morphological changes; and mean retinal
sensitivity in the treated retina according to morphological changes
observed in the retina. Level of statistical significance between
morphological changes and BCVA and retinal sensitivity is also
shown
Final BCVA (letters) MP 12º (dB) MP 2º (dB) MP PDT (dB)
ELM IS/OS
line
RPE ELM IS/OS
line
RPE ELM IS/OS
line
RPE ELM IS/OS
line
RPE
Normal 77.1±11.5 82.5±8.8 82±9.7 17.6±2.1 19.2±0.6 18±3.3 16.3±3.3 18.9±0.6 17.8±2.8 13.1±5.5 17.5±1.5 15.9±1.3
Interruptions – 74.8±12.1 – – 16.7±2.1 – – 15.2±2.9 – – 12.7±5.2 –
Atrophy – – 66.3±22.2 – – 15.1±5.6 – – 13.6±5.6 10.5±6.9
Absent 25±7.1 37.7±22.5 – 3.5±2.3 7.4±6.9 – 3.7±2.2 5.8±3.9 – 8.5±8 7.7±6.7 –
p 0.015 0.014 0.064 0.015 0.003 0.082 0.015 0.002 0.064 0.078 0.027 0.245
ELM external limiting membrane. IS/OS photoreceptor inner and outer segment junction. RPE retinal pigment epithelium. MP 12° central 12°
retinal sensitivity; MP 2°=central 2° retinal sensitivity: MP PDT retinal sensitivity within the treated retina
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subfoveal CTof the unaffected fellow eyes, which was 282.2±
60 μm (p=0.867, paired samples test). The final BCVA
showed no statistical correlation with the subfoveal CT, when
considering all the eyes or only those which received foveal
treatment (p=0.526 and p=0.256 respectively, Pearson corre-
lation). Age and subfoveal CT showed a negative correlation
(R Pearson= −0.80, p<0.001; Spearman’s rho=−0.76,
p<0.001). CT was also measured in the corresponding area
of the treated retina, and themean thickness was 269.6±83 μm
(range 100–403 μm). Subdividing into areas of treatment, the
CTwas 276.4±62.3μm (range 201–387μm) in the foveal area
and 259.9±111.1 μm (range 100–403 μm) in the non-foveal
area. Subfoveal CT of the eyes that were treated in the foveal
area also showed no statistical difference between the normal
population (p=0.604, one-sample test).
Discussion
In the current study we evaluate the long-term chorioretinal
functional and morphological changes 5 or more years after
standard PDT for chronic CSC. Several studies have shown
favorable results with PDT in treating chronic CSC [4–16].
Our report is the first one to describe the efficacy, the safety,
and the chorioretinal changes 5 or more years after standard
PDT for chronic CSC. The presumed therapeutic mecha-
nism of action of PDT is closure of vascular channels in the
choriocapillaris, based on the notion that SRF accumulation
is caused by choroidal hyperpermeability [22, 23]. Howev-
er, there are some questions related to the PDT long-term
effect in retina. Some authors have described RPE changes
after PDT, probably related with hypoxic damage caused by
closure of vascular channels in the choriocapillaris [15].
Copete et al. [16] described NRT thinning 1 year after
PDT and other authors reported development of CNV and
reduction of macular function after PDT [17–19]. Therefore,
more recently, some authors suggest alternative therapeutic
protocols, reporting a favorable outcome, without retina
side-effects, when using reduced fluence or half-dose verte-
porfin [4–10]. Most of these studies offer no consistent data
regarding the benefits of these alternative treatment proto-
cols, mostly because of the small number of patients includ-
ed and short-term follow-up. Moreover, a direct correlation
of these chorioretinal changes with PDT is still lacking.
We evaluated 17 eyes treated with standard verteporfin
PDT, in which 58.8 % were treated in the foveal area and
41.2 % in the non-foveal area.
A significant improvement in BCVA was registered, and
resolution of the NSD occurred in 100 % of the eyes at the
final follow-up. Several different studies have also supported
Fig. 2 Case 13: MP-1 showed a mean retinal sensitivity in the central 12° and 2° of 19.5 dB and 18.8 dB respectively; in the foveal treated retina, mean
retinal sensitivity was 16.4 dB. Spectralis OCTshowed a subfoveal normal EML, IS/OS line and RPE; central subfoveal choroidal thickness was 217 μm
Fig. 3 Case 16: MP-1 showed a mean retinal sensitivity in the central
12° and 2° of 18.1 dB and 18.5 dB respectively; the dark circle shows
the non-foveal treated retina and the mean retinal sensitivity in that area
was 11 dB. Spectralis OCT of the smallest treated retina showed an
absent ELM and IS/OS line and atrophic RPE; choroidal thickness
below the treated retina was 330 μm
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the favorable results of standard PDT for chronic CSC
[11–16]. Cardillo Piccolino et al. [15] performed standard
PDT in 16 eyes with chronic CSC, and reported resolution
of NSD in 81 % and BCVA improvement (1–4 lines) in 69 %
of the eyes. Also Copete et al. [16] showed complete resolu-
tion of NSD in 100 % and improvement of BCVA in 60 % of
the eyes, 1 year after standard PDT. A longer follow-up is
reported by Silva et al. [24], with a resolution of NSD in
93.4 % and an improvement of BCVA in 74 %, 4 years after
standard PDT. In the present study, CMT showed a statistical-
ly significant reduction, 5 years after standard PDT, corrobo-
rating the effectiveness of long-term standard PDT treatment
in the resolution of NSD. The neuroretinal thickness remained
unchanged during the 5 years of follow-up, demonstrating that
treatment with standard PDT did not induced neuroretinal
atrophy. Silva et al. [24] also did not find neuroretinal thick-
ness thinning 4 years after standard PDT. These results are
different from that reported by Copete et al. [16], which
showed neuroretinal thickness thinning 1 year after standard
PDT. The mean number of treatments was 1.1±0.3, and only
two eyes (11.8 %) underwent two treatment sessions. These
numbers of recurrence are inferior to others found in shorter
follow-up series, consolidating standard PDT long-term effec-
tiveness [13–15].
In our study, Spectralis CT analysis performed 5 or more
years after PDT showed subfoveal morphological changes
in ELM and IS/OS line that were statistically correlated with
final BCVA. Retinal morphological changes after PDT were
also reported in other studies. Cardillo Piccolino et al. [15]
reported RPE changes after standard PDT in 38.5 % of eyes,
of which 60 % showed RPE atrophy. In another study,
Cardillo Piccolino et al. [25] showed that impairment of
the photoreceptor layer in CSC was highly correlated with
visual loss. In this study, the four eyes that underwent PDT
had an atrophic outer photoreceptor layer at baseline, and
absent outer photoreceptor layer at final examination [25].
Moon et al. [26] demonstrated that one of the factors limit-
ing visual improvement after PDT for CSC was foveal
IS/OS damage. Kim et al. [27] documented that preserved
outer photoreceptor layer and continuity of IS/OS line were
correlated with better final BCVA. Ooto et al. [28] also
showed that visual loss was associated with abnormal cone
mosaic patterns and reduced cone densities in eyes with
resolved CSC. None of these studies fully demonstrate that
the alterations found were caused by the treatment. In our
study, the morphological changes found in ELM and IS/OS
line were statically correlated with BCVA, but not with the
variation of BCVA. Therefore, even eyes with absent ELM
or IS/OS line and atrophic RPE were able to improve vision
after standard PDT. This means that although eyes with
morphological changes in ELM and IS/OS line had the
worst BCVA, an improvement in BCVA was achieved with
PDT. Another important finding in this study was that
morphological changes were not correlated with the area
where the treatment was performed, whether it was in the
foveal or in the non-foveal area. Therefore, the reported
morphological changes in ELM, IS/OS line, and RPE
appeared in the foveal area even when the treatment was
performed in the non-foveal area. These results show that
5 years after standard PDT, there were morphological
changes in the retina, explained, probably, by the natural
course of the chronic disease and not induced by the stan-
dard PDT treatment.
Visual acuity is the standard way to measure visual
function, but it does not describe the full extent of the
impact on visual function in patients with compromised
central visual fields due to chronic CSC. Microperimetry
offers the option to test RS while directly observing the
fundus, providing the possibility to correlate subjective or
clinical changes with visual function. One of the main
symptoms of CSC is relative scotoma induced by lower
RS in the central visual field. Therefore, RS provides further
information concerning the visual function after treatment
with PDT. The MP-1 microperimeter allows automated
functional analysis of the macula, associated with real-time
correction of eye movements. Studies with microperimetry
in eyes with CSC show significantly lower RS not only at
the central but also in the paracentral area of the macula
[29–32]. Furthermore, Ozdemir et al. [33] found that eyes
with resolved CSC had a statistically significant reduced
central RS compared with controls. Although many studies
have shown improvement in visual function after PDT
[29–32], the improvement in BCVA may not be accompa-
nied by an improvement in central RS. Ehrlich et al. [34]
reported a statistically significant difference between the
proportions of patients who improved BCVA compared with
eyes who improved central RS. In our study, the mean final
RS in the central 12° and 2° were correlated with final
BCVA, but showed no correlation with the variation of the
BCVA. This means that decreased RS is probably more
related to retinal changes associated with the disease, than
to the effect of PDT, suggesting the absence of treatment-
induced adverse effects. In fact, many studies have reported
improvement of RS after PDT [29–32]. Fujita et al. [30]
showed improvement in RS within the area of serous retinal
detachment, as well as in the central 2° in diameter, 3 months
after half-dose verteporfin PDT. Senturk et al. [31] also
reported significant improvement in RS in the central 10°
and 20° and in the PDT laser spot area after half-dose
verteporfin PDT. Although in our study we had no data
assessing the RS before PDT, the final central RS is similar
to the results found in other studies [29–32]. To explain the
decreased RS despite the improvement in visual acuity, we
studied the morphological changes in the IS/OS line, in the
subfoveal, and in the PDT spot area. We found a positive
correlation between RS and morphological changes in the
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IS/OS line, and that sensitivity was better in eyes with
normal IS/OS line than in eyes with absent IS/OS line.
Fujita et al. [35] demonstrated that there is a significant
improvement in macular sensitivity after half-dose PDT in
eyes with chronic CSC, and that improvement was correlat-
ed with the recovery of the IS/OS line. Ojima et al. [36] also
showed that defects in IS/OS line were associated with
decreased RS. In their study, irregular RPE were also asso-
ciated with decreased RS [36]. In the present study, howev-
er, the morphological changes in the RPE showed no
correlation with the RS. Central RS was also correlated with
subfoveal ELM morphological changes; however, there
were only two eyes with absent ELM, and these two eyes
had retinal atrophy and poor prognosis—therefore we be-
lieve that this result is not relevant. Accordingly, decreased
RS may reflect photoreceptor dysfunction or photoreceptor
cell loss, and preserved visual acuity in eyes with reduced
central sensitivity is probably the result of reduced foveal
and parafoveal photoreceptor density. This corroborates the
fact that the assessment of the BCVA may underestimate
visual function after successful PDT treatment, and that
patients with active CSC may benefit from early treatment,
instead of conservative management, to resolve NSD before
chronic irreversible damage has occurred in the IS/OS line.
If CSC is caused by choroidal vascular hyperpermeability,
CT may be compromised. To examine this possibility, a
methodwas developed to evaluate CT, which consists in using
EDI OCT [37]. Studies with EDI OCT in eyes with CSC, or
even unaffected fellow eyes, show that the choroid is much
thicker than in normal eyes [38–40]. Imamura et al. [38]
reported a mean CT of 505 μm in eyes with CSC, which
was statistically greater than in normal eyes. The thickening of
the choroid was present in both eyes, even if the manifesta-
tions of CSC were present in one eye [38], suggesting the
systemic etiology of the disease. Margolis et al. [21] found
that the mean subfoveal CT in a normal population, with
similar age to those in our study, was 287 μm. Our results
showed that the subfoveal CT 5 years after standard PDTwas
not different from the thickness of the unaffected fellow eyes,
or from the thickness of the normal population. Also, the eyes
that were treated in the foveal area had a normal final sub-
foveal CT. A negative correlation between age and CT was
registered, as occurs with the normal population [21]. There-
fore, 5 years after successful standard PDT treatment, CT
showed normal values. Other studies have reported decrease
in CTafter PDT; however, the mean subfoveal CT in our study
is less than in others with shorter follow-up [41, 42]. Maruko
et al. reported a mean subfoveal CTof 330±103μm and 321±
68.6 μm 4 weeks and 1 year after half-dose verteporfin PDT
[41, 42]. Our results support the long-term effectiveness of
standard PDT, which eventually reduced CT and, probably,
the choroidal hyperpermeability responsible for the leakage
from the level of the RPE.
There are some limitations in our study including the
small sample, the retrospective design, the subjective clas-
sification of retinal layers, and the limited information prior
to PDT, since we used the Stratus OCT at the baseline.
However, our functional and anatomical results are impor-
tant to better understand the role of standard PDT in chronic
CSC, a disease without established treatment.
In conclusion, our long-term results showed that morpho-
logical and functional chorioretinal changes, observed at
least 5 years after standard PDT for chronic CSC, were not
correlated with the progression of visual acuity or with the
location of treatment, and are more likely to be related to the
disease itself than to the treatment provided. However, ran-
domized, prospective studies with larger numbers of
patients included are needed to determine the exact role of
and the appropriate protocol for photodynamic therapy in
patients with chronic CSC.
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